cabergoline has been researched along with Insulin Resistance in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Arnesi, M; Auriemma, RS; Cappabianca, P; Cavallo, LM; Colao, A; de Angelis, C; Negri, M; Pirchio, R; Pivonello, C; Pivonello, R; Solari, D | 1 |
| Kowalcze, K; Krysiak, R; Okopień, B | 2 |
| Bredella, MA; Dichtel, LE; Gerweck, AV; Miller, KK; Schorr, M; Swearingen, B; Woodmansee, WW; Young, BJ | 1 |
| Abdullah, N; Aboelnaga, MM; Eladawy, EH; Elshafei, MM; Shaer, ME | 1 |
| Amato, MC; Ciresi, A; Giordano, C; Guarnotta, V; Lo Castro, F | 1 |
| Auriemma, RS; Colao, A; Galdiero, M; Gasperi, M; Giordano, C; Granieri, L; Mannarino, T; Negri, M; Perone, Y; Pivonello, C; Pivonello, R; Simeoli, C; Vitale, P | 1 |
| Figueroa-Núñez, C; González, E; Gutierrez, M; Hernán Martínez, J; Mangual-García, M; Mansilla-Letelier, P; Miranda, Mde L; Palermo-Garofalo, C; Sánchez, A; Santiago, M; Torres, O; Trinidad, R | 1 |
| Krysiak, R; Okopien, B | 1 |
| Bonaventura, MM; Calandra, RS; Huhtaniemi, IT; Lux-Lantos, VA; Poutanen, M; Ratner, LD; Rulli, SB; Stevens, G | 1 |
| Cappabianca, P; Colao, A; De Leo, M; De Martino, MC; Faggiano, A; Hofland, LJ; Lamberts, SW; Lombardi, G; Pivonello, R | 1 |
| Endo, T; Kawamura, S; Maruta, M; Sakai, A | 1 |
| Barbosa, FR; Domingues, RC; dos Santos Silva, CM; Fontes, R; Gadelha, MR; Lima, GA; Warszawski, L | 1 |
| Cakir, B; Caner, S; Ersoy, R; Inancli, SS; Tam, AA; Usluogullari, A; Ustu, Y | 1 |
| Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM | 1 |
| Beauchamp, MC; Li, L; Maingrette, F; Mamputu, JC; Renier, G; Serri, O | 1 |
| Brändle, M; Schmid, C | 1 |
| Colao, A; Di Somma, C; Lombardi, G; Pivonello, R; Savastano, S; Tauchmanovà, L | 1 |
3 trial(s) available for cabergoline and Insulin Resistance
| Article | Year |
|---|---|
Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Topics: Adult; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Insulin Resistance; Insulin-Like Growth Factor I; Lipids; Middle Aged; Prolactin; Risk Factors | 2015 |
Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Biomarkers; Cabergoline; Carotid Intima-Media Thickness; Ergolines; Female; Glucose Tolerance Test; Humans; Inflammation; Insulin Resistance; Middle Aged; Pituitary Neoplasms; Prolactinoma; Young Adult | 2013 |
The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Topics: Adult; Biomarkers; Blood Glucose; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; E-Selectin; Enzyme-Linked Immunosorbent Assay; Ergolines; Female; Humans; Hyperprolactinemia; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Linear Models; Lipids; Male; Middle Aged; Obesity; Risk Factors; Tumor Necrosis Factor-alpha | 2006 |
15 other study(ies) available for cabergoline and Insulin Resistance
| Article | Year |
|---|---|
Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
Topics: Adult; Blood Glucose; Cabergoline; Combined Modality Therapy; Dopamine Agonists; Female; Humans; Insulin; Insulin Resistance; Male; Metabolome; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Treatment Outcome; Young Adult | 2021 |
Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
Topics: Androgens; Atorvastatin; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Insulin Resistance; Pilot Projects; Prolactin; Risk Factors; Uric Acid | 2022 |
Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Cholesterol; Creatinine; Female; Fibrinogen; Glycated Hemoglobin; Hashimoto Disease; Humans; Hyperprolactinemia; Insulin Resistance; Lipoproteins, HDL; Prolactin; Risk Factors; Thyroiditis, Autoimmune; Uric Acid | 2023 |
Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly.
Topics: Acromegaly; Adipose Tissue; Adult; Aged; Blood Glucose; Body Composition; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Ergolines; Female; Gonadal Steroid Hormones; Human Growth Hormone; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Lipid Metabolism Disorders; Lipodystrophy; Male; Middle Aged; Peptides, Cyclic; Prednisone; Somatostatin | 2017 |
Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.
Topics: Adult; Anthropometry; Body Weight; Cabergoline; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Insulin Resistance; Metabolome; Middle Aged; Prolactinoma; Treatment Outcome; Waist Circumference; Young Adult | 2019 |
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
Topics: Adiposity; Adult; Blood Glucose; Body Mass Index; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Insulin Resistance; Lipids; Male; Metabolome; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Waist Circumference; Young Adult | 2013 |
Effect of cabergoline on metabolism in prolactinomas.
Topics: Adiposity; Adult; Antineoplastic Agents; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Fasting; Female; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Male; Metabolic Diseases; Metabolic Syndrome; Pituitary Neoplasms; Prevalence; Prognosis; Prolactin; Prolactinoma; Prospective Studies; Time Factors; Treatment Outcome | 2013 |
Young female with acromegaloid features and pituitary macroadenoma: what is your diagnosis?
Topics: Acanthosis Nigricans; Acromegaly; Adult; Bromocriptine; Cabergoline; Diagnosis, Differential; Ergolines; Female; Gastrointestinal Diseases; Hirsutism; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prognathism; Prolactinoma | 2014 |
Hyperprolactinemia induced by hCG leads to metabolic disturbances in female mice.
Topics: Animals; Blood Glucose; Cabergoline; Chorionic Gonadotropin, beta Subunit, Human; Ergolines; Female; Glucose Intolerance; Hyperinsulinism; Hyperprolactinemia; Hypertriglyceridemia; Insulin; Insulin Resistance; Mice; Mice, Transgenic; Prolactin; Triglycerides | 2016 |
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
Topics: Adrenocorticotropic Hormone; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Insulin Resistance; Male; Middle Aged; Pituitary ACTH Hypersecretion | 2009 |
Conduct disorder in an adolescent girl treated with an insulin-sensitizing agent.
Topics: Adolescent; Cabergoline; Conduct Disorder; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Menarche; Pioglitazone; Polycystic Ovary Syndrome; Psychiatric Status Rating Scales; Thiazolidinediones; Violence | 2008 |
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Topics: Adult; Aftercare; Aged; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Bromocriptine; Cabergoline; Cholesterol, HDL; Cholesterol, LDL; Dopamine Agonists; Ergolines; Female; Humans; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metabolome; Middle Aged; Obesity; Prevalence; Prolactinoma; Waist Circumference; Weight Gain; Young Adult | 2011 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss | 2004 |
The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Topics: Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Insulin Resistance; Obesity; Risk Factors | 2006 |
Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome.
Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Body Height; Body Mass Index; Bromocriptine; Cabergoline; Combined Modality Therapy; Ergolines; Female; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Headache; Hormone Antagonists; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Male; Menstruation Disturbances; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Treatment Outcome | 2007 |